Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
GEORGE WESTON LIMITED	WN	Toronto S.E. +3 Other	110,078	190.5 CAD	Stock
GEORGE WESTON LIMITED	WX5	Deutsche Boerse AG	-	129 EUR
GEORGE WESTON LIMITED	WX5	BOERSE MUENCHEN	-	129 EUR
GEORGE WESTON LIMITED	WNGRF	OTC Markets	3,584	136.5 USD
GEORGE WESTON LIMITED	WN.PRC	Toronto S.E. +2 Other	5,615	20.38 CAD	Stock
GEORGE WESTON LIMITED	WNGP.F	OTC Markets	0	14.19 CAD
GEORGE WESTON LIMITED	WNGPF	OTC Markets	0	13.95 USD
GEORGE WESTON LIMITED	WN.PRA	Toronto S.E. +1 Other	5,758	22.46 CAD	Stock
GEORGE WESTON LIMITED	WGEGF	OTC Markets	-	- USD
GEORGE WESTON LIMITED	WN.PRD	Toronto S.E.	14,995	20.31 CAD	Stock
GEORGE WESTON LIMITED	WN.PRE	Toronto S.E.	5,497	18.67 CAD	Stock
GEORGE KENT (MALAYSIA)	GKENT	BURSA MALAYSIA	291,087	0.465 MYR	Stock
GEORGE RISK INDUSTRIES, INC.	RSKIA	OTC Markets	2,016	12.87 USD	Stock
ST GEORGE MINING LIMITED	SGQ	Australian S.E. +1 Other	833,691	0.019 AUD	Stock
ST GEORGE MINING LIMITED	S0G	Deutsche Boerse AG	-	0.007 EUR
RSE ARCHIVE LLC - MEMBERSHIP INTERESTS SERIES - 1780 GEORGE WASHINGTON LETTER FUND	RGWLS	OTC Markets	0	- USD	Stock

News (380)

Transcript : Voyager Therapeutics, Inc., Q2 2023 Earnings Call, Aug 03, 2023	03/08/23
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results	03/08/23	AQ
Transcript : Voyager Therapeutics, Inc., Q1 2023 Earnings Call, May 09, 2023	09/05/23
VOYAGER THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	09/05/23	AQ
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results	09/05/23	AQ
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors	09/05/23	AQ
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee	09/05/23	CI
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results	04/05/23	GL
AGILENT TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	17/03/23	AQ
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results	23/02/23	GL
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results	23/02/23	AQ
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK's National Institute for Health and Care Excellence	23/02/23	AQ
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)	22/02/23	GL
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)	22/02/23	AQ
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer	16/02/23	GL
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer	16/02/23	AQ
Vir Biotechnology Announces Amended Collaboration Agreement with GSK	13/02/23	GL
Vir Biotechnology Announces Amended Collaboration Agreement with GSK	13/02/23	GL
VIR BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)	25/01/23	AQ
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor	25/01/23	GL
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor	25/01/23	AQ
Vir Biotechnology, Inc. Announces CEO Changes	25/01/23	CI
Transcript : Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM	10/01/23
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference	03/01/23	GL
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500	17/11/22	AQ
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™	16/11/22	GL
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™	16/11/22	AQ
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results	03/11/22	GL
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results	03/11/22	AQ
Vir Biotech gets U.S. funding for flu-prevention antibody	04/10/22	RE
Vir Biotechnology : Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Form 8-K	09/08/22	PU
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results	09/08/22	GL
Vir Biotechnology Announces Transition of Chief Scientific Officer	14/07/22	GL
Vir Biotechnology Announces Transition of Chief Scientific Officer	14/07/22	GL
VIR BIOTECHNOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	24/05/22	AQ
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results	05/05/22	GL
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results	05/05/22	AQ
Transcript : Vir Biotechnology, Inc. - Special Call	27/04/22
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day	27/04/22	GL
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day	27/04/22	GL
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day	13/04/22	AQ
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge	06/04/22	GL
AGILENT TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	17/03/22	AQ
Vir Biotechnology : Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K	24/02/22	PU
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results	24/02/22	AQ

1234NextSee all

Companies (68)

GEORGE WESTON LIMITED 18 567 M $

George Weston Limited is a Canada-based company. The Company operates through two segments: Loblaw Companies Limited (Loblaw) and Choice Properties Real Estate Investment Trust (Choice Properties). Loblaw has two reportable operating segments, retail and ...

GEORGE WESTON LIMITED 18 567 M $

PERNOD RICARD SA 40 267 M $

Pernod Ricard is the world's No. 2 in the production and marketing of Premium and Prestige spirits and wines. Net sales break down by family of products as follows: - spirits and champagnes of strategic international brands (63.4%): Absolut (12.7 million ...

PERNOD RICARD 40 267 M $

TAYLOR WIMPEY PLC 6 225 M $

Taylor Wimpey plc is one of the leading British home builders. Net sales break down by activity as follows: - construction and sale of homes (98.7%): activity assured in the United Kingdom (George Wimpey, G2, Wilson Connolly and Laing Homes brands), Nort ...

TAYLOR WIMPEY PLC 6 225 M $

GEORG FISCHER AG 6 011 M $

Georg Fischer AG is a Switzerland-based company engaged in the development of systems for industrial applications. The Company operates through three business segments: GF Piping Systems, GF Casting Solutions, and GF Machining Solutions. GF Piping Systems ...

1234Next

Insiders

George Scangos

George A. Scangos is a businessperson who has been the head of 10 different companies and currently occupies the position of President, Chief Executive Officer & Director at Vir Biotechnology, Inc. He is also Member-National Board of Visitor at the University of California and on the board of 5 other companies. In his past career George A. Scangos held the position of Director at Decibel Therapeutics, Inc., Chief Executive Officer & Director at Biogen, Inc. Chief Executive Officer at Biogen Idec New Ventures, Inc. and Chief Executive Officer of Biogen Idec, Inc. (North Carolina) (both are subsidiaries of Biogen, Inc.), President, Chief Executive Officer & Director at Exelixis, Inc., President for Bayer Biotechnology, Chairman of Anadys Pharmaceuticals, Inc., Chairman of California Healthcare Institute, Senior Vice President-Research & Development at Bayer, Inc., President-Biotechnology Division at Bayer Corp., Chairman for Pharmaceutical Research & Manufacturers of America and Professor at The Johns Hopkins University. He received a doctorate from the University of Massachusetts and an undergraduate degree from Cornell University.

George Milton George

George Milton George worked as a Chief Financial Officer at Middle East Paper Co.

George Koikkattil George

George George

George T. George

George M George

George Muthoot George

George Muthoot George currently works as a Director at Muthoot Securities Ltd.

George Muthoot George

George Muthoot George is currently the Executive Director & Co-Deputy MD at Muthoot Finance Ltd.
He is also a Director at Muthoot Broadcasting Pvt Ltd., Muthoot Securities Ltd., Muthoot Insurance Brokers Pvt Ltd., Muthoot Anchor House Hotels Pvt Ltd., Muthoot Holidays Pvt Ltd., and Patgaon Plantations Pvt Ltd.
Additionally, he holds the position of Managing Director at Xandari Pearl Beach Resorts Pvt Ltd.
and Muthoot Leisure & Hospitality Services Pvt Ltd.
In terms of education, Mr. George is a graduate of ESSEC Business School and holds an undergraduate degree from Welcomgroup Graduate School of Hotel Administration.

No results for this search